Skip to main content
. 2020 Apr 27;10:7067. doi: 10.1038/s41598-020-63904-w

Table 1.

Participant characteristics.

n Subset Full
294 892
Age at diagnosis: mean (SD) 57.9 (12.7) 59.3 (12.8)
Stage = invasive (%) 262 (89.1) 768 (86.1)
Race = white (%) 274 (93.2) 835 (93.6)
Menopausal status = postmenopausal (%) 189 (65.6) 605 (67.8)
Parity = 1 or more (%) 254 (86.4) 769 (86.2)
Lactated (%) 96 (32.7) 292 (32.7)
Age at menarche: mean (SD) 12.6 (1.6) 12.5 (1.6)
Age at first birth: mean (SD) 25.7 (4.8) 25.7 (4.9)
Oral contraceptive use (%) 141 (48.0) 377 (42.3)
Hormone replacement therapy use (%) 82 (28.0) 246 (27.6)
Current or past smoker (%) 165 (56.1) 485 (54.3)
Alcohol (%) 180 (61.2) 556 (62.3)
BMI: mean (SD) 26.9 (6.1) 26.9 (5.8)
Education:
        ≤High School 142 (48.5) 443 (49.8)
        College 112 (38.2) 316 (35.5)
        Post-college 39 (13.3) 131 (14.7)
Income:
        ≤$24,999 50 (19.5) 175 (22.2)
        $25,000-$49,999 90 (35) 237 (30.2)
        ≥$50,000 117 (45.5) 374 (47.6)

All LIBCSP women with urinary MEP measurements (n = 892) compared with subset with both urinary MEP measurement and DEP gene signature measurement in pre-malignant adjacent tissues (n = 294).